Abstract
The 2023 clinical practice guidelines for diabetes in Korea are reviewed and updated biennially by the Committee of Clinical Practice Guidelines of the Korean Diabetes Association based on the latest scientific research and clinical trials. The 2023 guidelines include several updates to recommendations for pharmacological treatment of type 2 diabetes. The new guidelines make it clear that the treatment plan should include antidiabetic agents proven to reduce cardiorenal risk in adults with type 2 diabetes and established atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease. When considering injection-based combination therapy, GLP-1 receptor agonists (GLP-1 RAs) are recommended prior to basal insulin. If the target blood glucose level cannot be reached with GLP-1 RAs or basal insulin treatment alone, combination treatment with GLP-1 RAs and basal insulin is recommended. This review summarizes the recommendations for pharmacological treatment for type 2 diabetes in the 2023 Korean Diabetes Association treatment guidelines, focusing on major revisions.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
